Related Experiment Video
Updated: Jul 17, 2026
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
The past, present and future of hypertension management: a potential role for AT(1)-receptor antagonists
Insights
Effective antihypertensive treatment is crucial, yet blood pressure control remains a challenge. Angiotensin II receptor blockers offer a promising solution with good tolerability and potential to prevent organ damage.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Despite established benefits of antihypertensive therapy, blood pressure control is often inadequate.
- Current treatments face challenges in long-term efficacy, tolerability, and patient compliance.
Discussion:
- Angiotensin II type 1 (AT(1)) receptor blockade is a targeted approach to counteract angiotensin II's adverse cardiovascular effects.
- AT(1)-receptor blockers demonstrate significant antihypertensive efficacy combined with exceptional, placebo-like tolerability.
- These agents have shown promise in preventing and reversing target organ damage in preclinical models.
Key Insights:
- AT(1)-receptor blockers represent a unique class of antihypertensive drugs with favorable tolerability profiles.
- These drugs offer a rational strategy for achieving sustained blood pressure reduction and protecting vital organs.
- Experimental data suggest protective effects on the heart, vasculature, and kidneys.
Outlook:
- Large-scale outcome studies are ongoing to confirm the benefits of AT(1)-receptor blockade beyond blood pressure reduction.
- Further research will elucidate the full potential of these agents in cardiovascular disease management.
- The unique tolerability profile may improve long-term patient adherence and treatment outcomes.
Abstract:
The benefits of effective antihypertensive treatment were established at least 40 years ago, but despite the availability of more reliable and better-tolerated antihypertensive drugs, the control of blood pressure remains poor in most patients. Long-term antihypertensive efficacy requires treatment that combines reliable 24-hour reduction of blood pressure with good tolerability to facilitate patient compliance. Treatment should also protect against target-organ damage. As the majority of negative cardiovascular effects of angiotensin II are mediated through the angiotensin II type 1 (AT(1)) receptor, specific blockade of this receptor is a rational approach for achieving these ideals. Several AT(1)-receptor blockers have been developed that combine antihypertensive efficacy and placebo-like tolerability - the latter being unique in the history of antihypertensive therapy. In experimental animals these drugs prevent or reverse target organ damage in the heart, the vasculature and the kidney. Ongoing large-scale outcome studies are now underway to establish the benefits of AT(1)-receptor blockade beyond blood pressure control.
Related Concept Videos
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:17Antihypertensive Drugs: Action of β1 Blockers
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications